
Futures slip amid renewed tariff-related uncertainty
Wall Street Breakfast
00:00
Novo Nordisk trial setback details
Julie Morgan explains Novo Nordisk's stock drop after its obesity drug underperformed Eli Lilly's tirzepatide in phase three.
Play episode from 04:45
Transcript


